Category Archives: Drug prices

Patient commentary: the current model has failed

Source: BMJ The cost of cancer drugs is skyrocketing: prices of cancer drugs increased by 10% every year between 1995 and 2013.1 More and more we’re seeing cancer drugs being priced off the NHS—as is the case with secondary breast cancer … Continue reading

Posted in Cancer, Drug prices, R&D, Uncategorized | Leave a comment

Delhi HC seeks AAP govt report on plea for free treatment of Hepatitis C

Source: PTI Published: Zee News A bench of Acting Chief Justice Gita Mittal and Justice C Hari Shankar also issued notice to the Delhi Government on the petition which sought direction to identify and publicise the names of hospitals, laboratories and medical … Continue reading

Posted in Drug prices, Drugs, Hepatitis C, Uncategorized | Tagged , | Leave a comment

UACT ASKS CEOS FOR TRANSPARENCY ON CAR T TREATMENTS

Today, UACT submitted letters to the CEOs of three major pharmaceutical companies currently developing chimeric antigen receptor T-cell (CAR T) technologies.  UACT asked the leaders of Novartis, Gilead Sciences, and Juno Therapeutics to address questions regarding research and development (R&D) … Continue reading

Posted in Cancer, Drug prices, Gene Therapy, Patent, R&D, Uncategorized | Leave a comment

Trump’s Executive Order on Drug Prices Might Be More in Favour of Drug Companies

The order will likely be a far cry from the president’s previous remarks about the pharmaceutical industry. Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six-page document outlining the draft provisions or objectives of a proposed presidential executive … Continue reading

Posted in Drug prices, Patent, Patent Term Extension, Uncategorized | Leave a comment

 The Government Created This Zika Vaccine. Why Should Big Pharma Reap the Profits?

 Lawmakers are concerned that giving a drug company a monopoly on the promising vaccine could make it unaffordable. 

Posted in Drug prices, Patent, R&D, Uncategorized | Leave a comment

If Modi Really Wants Affordable Medicines, Why is His Niti Aayog Pushing in the Opposite Direction?

The government’s premier policy-formulating agency recently recommended measures to deregulate the pharmaceutical sector and make essential medicines more expensive. New Delhi: Even as the prime minister repeatedly expresses his commitment to providing affordable medicines in the country, it appears that the NITI Aayog … Continue reading

Posted in Drug prices, Innovation, Uncategorized | Leave a comment

Update from India on Xtandi (Enzalutamide) for cancer treatment

In January 2016, KEI and the Union for Affordable Cancer Treatment petitioned the US the Department of Health and Human Services or the National Institutes of Health to use the federal government rights in the patents on the prostate cancer … Continue reading

Posted in Cancer, Drug prices, Patent, Uncategorized | Tagged , , , | Leave a comment